[Update on targeted biopharmaceuticals in systemic sclerosis!]

Abstract

Systemic sclerosis (SSc) is a rare connective tissue disease characterized by inflammation, fibrosis, and autoimmunity. Despite few clinical trials when compared to other autoimmune diseases, SSc has benefited from renewed interest over the past ten years and a large number of clinical trials have been performed or are underway. We present here the results of the trials published in the last 5 years in ScS according to the chosen endpoint criteria and describe the trials in progress or expected in the years to come.

Keywords: Fibrose; Fibrosis; Interstitial lung disease; Pneumopathie interstitielle diffuse; Raynaud; Raynaud's phenomenon; Sclérodermie systémique; Systemic sclerosis; Traitement.